SK Biopharm has confirmed high tumor accumulation and survival extension effects in preclinical studies for its next-generation anti-cancer strategy, the 'NTSR1-targeted radiopharmaceutical' currently under development.

SK Biopharm corporate logo image. SK Biopharm

SK Biopharm corporate logo image. SK Biopharm

View original image

On April 6, SK Biopharm announced that it will present research results for its therapeutic agent 'SKL35501' and imaging diagnostic agent 'SKL35502' at the American Association for Cancer Research (AACR) annual meeting, which will be held in San Diego, United States, from April 17 to 22.


This presentation will publicly share the preclinical achievements of SK Biopharm's 'theranostics' strategy, which involves the simultaneous development of NTSR1-targeted therapeutics and diagnostics. Currently, SK Biopharm has advanced the development of this pipeline to the clinical stage in just about 18 months after its introduction.


The therapeutic agent 'SKL35501' is a radiopharmaceutical based on the alpha-emitting nuclide actinium-225. In a colorectal cancer cell line (HCT116) model, tumor accumulation was observed at a level of 31%ID/g 24 hours after administration. Target selectivity was maintained for up to 168 hours.


Even with a single administration, dose-dependent tumor growth inhibition and survival extension effects were confirmed. In some dosage groups, a reduction in tumor size was also observed. The drug was rapidly eliminated from non-target organs, demonstrating potential for safety as well.


The imaging diagnostic agent 'SKL35502' showed approximately 22 times higher tumor exposure compared to blood in the same model. At 96 hours post-administration, 84.12% of total radioactivity was excreted, indicating a low residual burden in normal tissues.


Both substances are based on a precision medicine approach that involves selecting patients with NTSR1 expression through imaging and then administering the same targeted therapeutic agent. NTSR1 is known to be overexpressed in various solid tumors, including colorectal and pancreatic cancers.


In January of this year, SK Biopharm obtained Phase 1 IND approval for both candidate substances from the Ministry of Food and Drug Safety as well as the U.S. Food and Drug Administration (FDA). Accordingly, the company is set to begin its first-in-human clinical trial with NTSR1-positive solid tumor patients.



Donghoon Lee, CEO of SK Biopharm, stated, "This AACR presentation is a meaningful opportunity to share, for the first time on a global stage, the research achievements of SK Biopharm's next-generation core RPT pipeline. We will continue to accelerate RPT development and continuously strengthen our global-level research and development capabilities to provide patients with innovative treatment options."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing